Newport Premium™ (for Generics), building on the heritage of Newport Horizon Global, is the most advanced product targeting, global business development and API sourcing system from Thomson Reuters, the industry authority on the global generics market.
Created specifically for demanding professionals in generic pharmaceutical companies, OTC and API manufacturers, it can help you to identify and evaluate new product development and licensing opportunities ahead of the competition for both small molecules and follow-on biologics.
Built on more than a decade’s experience supplying solutions to meet critical business challenges in today’s highly competitive and global generic and API markets, Newport products are now used by more than 250 companies operating in 50 countries around the world.
Powerful integrated API intelligence with unique analysis.
With Newport Premium (for Generics), you can:
- Build your development pipeline based on patents, sales trends, API availability, and competition for both small molecules and biologics.
- Recognize critical patent, exclusivity and regulatory issues with candidate products.
- Discover early, exclusive sources of API supply.
- Profile competitors, business partners, and candidate products for acquisition, alliances, licensing, or supply and manufacturing.
- Track and monitor the launch, API development and patenting activities of competitors across more than 90 countries worldwide, including India and China.
- Evaluate candidate products against the earliest competitive intelligence.
- Evaluate new product development opportunities in over 70 markets worldwide including India and China.
- Identify niche opportunities that match your strategic needs and unique research, sales or marketing strengths.
- Adjust your research timing, priorities and resources based on active competitive intelligence monitoring.
- Evaluate your pipeline based on kilogram API consumption data and trends and available routes of synthesis.
- Analyze and compare API consumption data and trends by region, and by dose form for the current and previous year.
- Analyze routes of synthesis together with required intermediates and reagents, in addition to the referenced patents and scientific literature.
- Find products that use particular intermediates or reagents.
Why choose Newport Premium (for Generics)?
- Unique strategic intelligence. Newport Premium incorporates the unique strategic intelligence and powerful competitive analysis that is only available from Thomson Reuters. It integrates intelligence on more than 40,000 launched products with 300,000+ brand names containing over 10,000 different active ingredients and over 20,000 corporate groups involved with manufacturing and marketing dose products and both small molecule and biologic active ingredients.
- Sophisticated targeting capabilities. Newport Premium can help you to build your product portfolio and profile promising new partner companies. API availability data and trends can be included in product-targeting searches, enabling you to find the most appropriate business opportunities quickly and accurately — in whichever world markets you work or need to develop.
- Test and explore new business strategies. Newport Premium can help you to recognize potential barriers to market entry, and plan your development pipeline effectively. With the industry’s most sophisticated product targeting capabilities, it can significantly enhance your competitive edge.
- Proven business value. In use for many years at more than 250 of the world’s leading generic companies and API manufacturers, and more than 80% of the industry’s Top 50 companies are customers.
Our intelligence for the generic and API industries is also available in less extensive configurations. To find out more about Newport GlobalTM (formerly known as Newport Horizon Global) or Newport SourcingTM (formerly known as Newport Horizon Sourcing) please contact us.
Product Intelligence
- Unique, early API manufacturing intelligence for 7,000 active ingredients.
- Regulatory filings, such as US and Japanese DMFs, Certificates of Suitability, Indian and Chinese Import Registrations, US DEA registration notices.
- Two years of regional sales and consumption data, worldwide launch, and pack price data for 40,000 launched products containing over 10,000 different active ingredients.1
- US market share breakdown by dose form and strength.
- US Orange Book, EU centralized procedure, and European first market authorization data.
- Labeling and prescribing data for more than 1,500 unique products.
- Chemical structure diagrams for thousands of products.
- Routes of synthesis, including intermediates and reagents with patent and literature references for 3000 products.2
- Powerful indexing and searching of products according to FDA approved indication and technology class.
- Proprietary analytics
Company Intelligence
- Profiles of more than 25,000 companies and corporate groups, including subsidiaries, finished dose launches, US approvals, regulatory filings, APIs manufactured, inspections by the US FDA and other regulatory agencies, and Warning Letters.
- Detailed manufacturing capabilities for 1000 API and biologic manufacturing sites and 500 contract dose manufacturing sites.3
- Company key financial indicators and sales forecasts
- Proprietary analytics and company ratings
Patents
- Worldwide patent families and individual patents for more than 90 countries.
- Comprehensive Supplementary Protection Certificate (SPC) data for Europe.4
- Projected loss of exclusivity dates for US, European and Japanese markets.
- Paragraph IV patent challenges commentaries, including company identities, FTF and status of litigation for more than 270 products.
Current Awareness
- Alerting on key changes in products and companies, including new regulatory filings, approvals, and patent challenges.
- Real-time news regarding products and companies.5
- Reports on key conferences affecting the generics industry.
1 IMS Health2 Prous Science, a Thomson Reuters business3 PharmSourceTM4 Cabinet Alice de Pastors5 AcquireMedia
Contact Us
Thomson Reuters
API Intelligence
215 Commercial Street
Portland, Maine 04101
Tel: +1 207.871.9700
Fax: +1 207.871.9800